Generic opportunity for Alchemia
Friday, 13 March, 2009
Alchemia’s manufacturing partner Dr Reddy’s Laboratories has filed an abbreviated new drug application with the US FDA for a generic version of fondaparinux, used to prevent blood clots.
Fondaparinux is currently marketed by GlaxoSmithKline under the brand name Atrixa, which came off patent in 2002.
No other company has filed an application for a generic in that time as fondaparinux is a difficult molecule to synthesise, Alchemia said.
It is hoped the FDA will review the application within six months of filing under a priority review system.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
